Pan-pan Liu

State Key Laboratory Of Oncology In South China
Guangzhou, 510060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Anti-CD3/CD20 bispecific antibodies as salvage therapy after CAR-T failure in relapsed/refractory large B-cell lymphoma: a systematic review and meta-analysis.

Anti-CD3/CD20 bispecific antibodies as salvage therapy after CAR-T failure in relapsed/refractory large B-cell lymphoma: a systematic review and meta-analysis.

Journal: Annals of hematology

Published: February 11, 2026

Anatomical laterality of primary intestinal diffuse large B-cell lymphoma independently stratifies survival: New prognostic nomogram incorporating tumor location.

Anatomical laterality of primary intestinal diffuse large B-cell lymphoma independently stratifies survival: New prognostic nomogram incorporating tumor location.

Journal: World journal of gastroenterology

Published: October 21, 2025

Predictive factors and nomogram for the risk of cytokine release syndrome with anti-CD3 × CD20 bispecific antibodies for Chinese patients.

Predictive factors and nomogram for the risk of cytokine release syndrome with anti-CD3 × CD20 bispecific antibodies for Chinese patients.

Journal: Cancer immunology, immunotherapy : CII

Published: February 14, 2025

Improved efficacy of concurrent anti-PD1 antibody plus AVD versus ABVD in patients with newly diagnosed early unfavorable and advanced stage classic Hodgkin lymphoma: a retrospective matched cohort study.

Improved efficacy of concurrent anti-PD1 antibody plus AVD versus ABVD in patients with newly diagnosed early unfavorable and advanced stage classic Hodgkin lymphoma: a retrospective matched cohort study.

Journal: Cancer immunology, immunotherapy : CII

Published: January 15, 2025

HKDC1 functions as a glucose sensor and promotes metabolic adaptation and cancer growth via interaction with PHB2.

HKDC1 functions as a glucose sensor and promotes metabolic adaptation and cancer growth via interaction with PHB2.

Journal: Cell death and differentiation

Published: May 12, 2024

First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial.

First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial.

Journal: The Lancet. Haematology

Published: October 27, 2023

Phase II Study of Gemcitabine, Peg-Asparaginase, Dexamethasone and Methotrexate Regimen for Newly Diagnosed Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Final Analysis With Long-Term Follow-Up and Rational Research for the Combination.

Phase II Study of Gemcitabine, Peg-Asparaginase, Dexamethasone and Methotrexate Regimen for Newly Diagnosed Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Final Analysis With Long-Term Follow-Up and Rational Research for the Combination.

Journal: Frontiers in oncology

Published: October 17, 2021

Modulation of energy metabolism to overcome drug resistance in chronic myeloid leukemia cells through induction of autophagy.

Modulation of energy metabolism to overcome drug resistance in chronic myeloid leukemia cells through induction of autophagy.

Journal: Cell death discovery

Published: October 05, 2021

Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma.

Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma.

Journal: British journal of haematology

Published: June 27, 2021

Chemical constituents with inhibition against TNF-α from Merrillanthus hainanensis.

Chemical constituents with inhibition against TNF-α from Merrillanthus hainanensis.

Journal: Fitoterapia

Published: April 07, 2021

Expression of PD-L1 on Monocytes Is a Novel Predictor of Prognosis in Natural Killer/T-Cell Lymphoma.

Expression of PD-L1 on Monocytes Is a Novel Predictor of Prognosis in Natural Killer/T-Cell Lymphoma.

Journal: Frontiers in oncology

Published: February 07, 2020

Synergy between Auranofin and Celecoxib against Colon Cancer In Vitro and In Vivo through a Novel Redox-Mediated Mechanism.

Synergy between Auranofin and Celecoxib against Colon Cancer In Vitro and In Vivo through a Novel Redox-Mediated Mechanism.

Journal: Cancers

Published: May 06, 2019

Showing 1-12 of 31

Last Updated: 09/26/2026